EpCAM Expression Varies Significantly and is Differentially Associated with Prognosis in the Luminal B HER2(+), Basal-like, and HER2 Intrinsic Subtypes of Breast Cancer

Overview

Journal Br J Cancer

Specialty Oncology

Date 2013 Mar 23

PMID 23519058

Citations 63

Authors

S D Soysal

S Muenst

T Barbie

T Fleming

F Gao

G Spizzo

D Oertli

C T Viehl

E C Obermann

W E Gillanders

Affiliations

Soon will be listed here.

Abstract

Background: Epithelial cell adhesion molecule (EpCAM) is frequently expressed in breast cancer, and its expression has been associated with poor prognosis. Breast cancer can be subdivided into intrinsic subtypes, differing in prognosis and response to therapy.

Methods: To investigate the association between EpCAM expression and prognosis in the intrinsic subtypes of breast cancer, we performed immunohistochemical studies on a tissue microarray encompassing a total of 1365 breast cancers with detailed clinicopathological annotation and outcomes data.

Results: We observed EpCAM expression in 660 out of 1365 (48%) cases. EpCAM expression varied significantly in the different intrinsic subtypes. In univariate analyses of all cases, EpCAM expression was associated with a significantly worse overall survival. In the intrinsic subtypes, EpCAM expression was associated with an unfavourable prognosis in the basal-like and luminal B HER2(+) subtypes but associated with a favourable prognosis in the HER2 subtype. Consistently, specific ablation of EpCAM resulted in increased cell viability in the breast cancer cell line SKBR3 (ER(-), PR(-), and HER2(+)) but decreased viability in the breast cancer cell line MDA-MB-231 (ER(-), PR(-), and HER2(-) ).

Conclusion: The differential association of EpCAM expression with prognosis in intrinsic subtypes has important implications for the development of EpCAM-targeted therapies in breast cancer.

Citing Articles

Association between EPCAM upregulation and clinicopathological parameters and outcomes of breast cancer.

Nafissi N, Azad Armaki S, Babaee E, Babaheidarian P, Safari E, Sayad S Int J Clin Exp Pathol. 2024; 17(11):421-428.

PMID: 39660329 PMC: 11626292. DOI: 10.62347/EGXS1506.

Tumor-derived EV miRNA signatures surpass total EV miRNA in supplementing mammography for precision breast cancer diagnosis.

Kim Y, Kim J, Moon S, Lee H, Lee S, Kim J Theranostics. 2024; 14(17):6587-6604.

PMID: 39479442 PMC: 11519808. DOI: 10.7150/thno.99245.

Characterization of EpCAM-Positive and EpCAM-Negative Tumor Cells in Early-Stage Breast Cancer.

Perelmuter V, Grigoryeva E, Alifanov V, Kalinchuk A, Andryuhova E, Savelieva O Int J Mol Sci. 2024; 25(20).

PMID: 39456890 PMC: 11508537. DOI: 10.3390/ijms252011109.

A Mem-dELISA platform for dual color and ultrasensitive digital detection of colocalized proteins on extracellular vesicles.

Sharma H, Yadav V, Burchett A, Shi T, Senapati S, Datta M Biosens Bioelectron. 2024; 267:116848.

PMID: 39413723 PMC: 11543507. DOI: 10.1016/j.bios.2024.116848.

Bio-Pathological Functions of Posttranslational Modifications of Histological Biomarkers in Breast Cancer.

Neagu A, Josan C, Jayaweera T, Morrissiey H, Johnson K, Darie C Molecules. 2024; 29(17).

PMID: 39275004 PMC: 11397409. DOI: 10.3390/molecules29174156.

References

Bubendorf L, Nocito A, Moch H, Sauter G . Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies. J Pathol. 2001; 195(1):72-9. DOI: 10.1002/path.893. View

Munz M, Kieu C, Mack B, Schmitt B, Zeidler R, Gires O . The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene. 2004; 23(34):5748-58. DOI: 10.1038/sj.onc.1207610. View

Sankpal N, Willman M, Fleming T, Mayfield J, Gillanders W . Transcriptional repression of epithelial cell adhesion molecule contributes to p53 control of breast cancer invasion. Cancer Res. 2009; 69(3):753-7. PMC: 3907266. DOI: 10.1158/0008-5472.CAN-08-2708. View

Goldhirsch A, Wood W, Coates A, Gelber R, Thurlimann B, Senn H . Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011; 22(8):1736-47. PMC: 3144634. DOI: 10.1093/annonc/mdr304. View

Tai K, Shiah S, Shieh Y, Kao Y, Chi C, Huang E . DNA methylation and histone modification regulate silencing of epithelial cell adhesion molecule for tumor invasion and progression. Oncogene. 2007; 26(27):3989-97. DOI: 10.1038/sj.onc.1210176. View

Spizzo G, Went P, Dirnhofer S, Obrist P, Simon R, Spichtin H . High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat. 2004; 86(3):207-13. DOI: 10.1023/B:BREA.0000036787.59816.01. View

Scheulen M, Dittrich C, Obrist P, Marschner N, Dirix L, Schmidt M . An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer. Ann Oncol. 2009; 21(2):275-282. DOI: 10.1093/annonc/mdp314. View

Tapia C, Zlobec I, Schneider S, Kilic E, Guth U, Bubendorf L . Deletion of the inhibitor of growth 4 (ING4) tumor suppressor gene is prevalent in human epidermal growth factor 2 (HER2)-positive breast cancer. Hum Pathol. 2011; 42(7):983-90. PMC: 3103605. DOI: 10.1016/j.humpath.2010.10.012. View

Cristofanilli M, Budd G, Ellis M, Stopeck A, Matera J, Miller M . Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8):781-91. DOI: 10.1056/NEJMoa040766. View

10.

Spizzo G, Went P, Dirnhofer S, Obrist P, Moch H, Baeuerle P . Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gynecol Oncol. 2006; 103(2):483-8. DOI: 10.1016/j.ygyno.2006.03.035. View

11.

van der Gun B, Melchers L, Ruiters M, de Leij L, McLaughlin P, Rots M . EpCAM in carcinogenesis: the good, the bad or the ugly. Carcinogenesis. 2010; 31(11):1913-21. DOI: 10.1093/carcin/bgq187. View

12.

Baeuerle P, Gires O . EpCAM (CD326) finding its role in cancer. Br J Cancer. 2007; 96(3):417-23. PMC: 2360029. DOI: 10.1038/sj.bjc.6603494. View

13.

Sankpal N, Mayfield J, Willman M, Fleming T, Gillanders W . Activator protein 1 (AP-1) contributes to EpCAM-dependent breast cancer invasion. Breast Cancer Res. 2011; 13(6):R124. PMC: 3326566. DOI: 10.1186/bcr3070. View

14.

Schmidt M, Ruttinger D, Sebastian M, Hanusch C, Marschner N, Baeuerle P . Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancer. Ann Oncol. 2012; 23(9):2306-2313. DOI: 10.1093/annonc/mdr625. View

15.

Songun I, Litvinov S, van de Velde C, Pals S, Hermans J, van Krieken J . Loss of Ep-CAM (CO17-1A) expression predicts survival in patients with gastric cancer. Br J Cancer. 2005; 92(9):1767-72. PMC: 2362035. DOI: 10.1038/sj.bjc.6602519. View

16.

Agboola A, Paish E, Rakha E, Powe D, Macmillan R, Ellis I . EpCAM expression is an indicator of recurrence in basal-like breast cancer. Breast Cancer Res Treat. 2011; 133(2):575-82. DOI: 10.1007/s10549-011-1813-7. View

17.

Perou C, Sorlie T, Eisen M, van de Rijn M, Jeffrey S, Rees C . Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-52. DOI: 10.1038/35021093. View

18.

Litvinov S, Bakker H, Gourevitch M, Velders M, Warnaar S . Evidence for a role of the epithelial glycoprotein 40 (Ep-CAM) in epithelial cell-cell adhesion. Cell Adhes Commun. 1994; 2(5):417-28. DOI: 10.3109/15419069409004452. View

19.

Spizzo G, Fong D, Wurm M, Ensinger C, Obrist P, Hofer C . EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis. J Clin Pathol. 2011; 64(5):415-20. PMC: 3088404. DOI: 10.1136/jcp.2011.090274. View

20.

Herlyn M, Steplewski Z, Herlyn D, KOPROWSKI H . Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. Proc Natl Acad Sci U S A. 1979; 76(3):1438-42. PMC: 383267. DOI: 10.1073/pnas.76.3.1438. View